Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Janus kinase inhibitors
9 evidence topics · 11 sources
ACG 2025 guideline: recommendations for induction and maintenance
Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary
U.S. positioning after TNF antagonist failure: ACG 2025
Restricted first-line use: AGA 2024 guideline
ECCO 2026 guideline: recommendations, safety, and European risk minimization
Tofacitinib: U.S. indication in ulcerative colitis
Upadacitinib: U.S. indication and dosing in ulcerative colitis
Network meta-analyses: rankings of Janus kinase inhibitors
“With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab with low to moderate certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib and ustekinumab were ranked highest for achieving remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upadacitinib ranked highest in inducing clinical remission (99.6%), and endoscopic improvement (99.2%), followed by risankizumab (91.4%) and (82.3%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In re‐randomised studies, upadacitinib 30 mg o.d. ranked first for clinical remission (RR of failure to achieve clinical remission = 0.52; 95% CI 0.44–0.61, p‐score 0.99) and endoscopic improvement (RR = 0.43; 95% CI 0.35–0.52, p‐score 0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The guideline does not provide a hierarchy of treatments, due predominantly to the lack of head-to-head data, but network meta-analysis (NMA) of trials for induction and maintenance of moderate to severe UC demonstrate a large magnitude of effect for upadacitinib and tofacitinib, with moderate magnitude of effect for risankizumab, filgotinib and ozanimod, and a small magnitude of effect for infliximab, etrasimod, golimumab, mirikizumab, ustekinumab and vedolizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote